Northern Trust Corp Argenx Se Transaction History

Northern Trust Corp

  • $600 Billion
  • Q3 2024

A detailed history of Northern Trust Corp transactions in Argenx Se stock. As of the latest transaction made, Northern Trust Corp holds 37,940 shares of ARGX stock, worth $21.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,940
Previous 36,326 4.44%
Holding current value
$21.4 Million
Previous $15.6 Million 31.72%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$434.22 - $551.9 $700,831 - $890,766
1,614 Added 4.44%
37,940 $20.6 Million
Q2 2024

Aug 14, 2024
BUY
$356.01 - $451.55 $747,264 - $947,803
2,099 Added 6.13%
36,326 $15.6 Million
Q1 2024

May 14, 2024
BUY
$356.95 - $413.29 $1.03 Million - $1.19 Million
2,887 Added 9.21%
34,227 $13.5 Million
Q4 2023

Feb 13, 2024
SELL
$338.91 - $506.01 $2.91 Million - $4.35 Million
-8,596 Reduced 21.52%
31,340 $11.9 Million
Q3 2023

Nov 13, 2023
BUY
$369.35 - $548.43 $4.29 Million - $6.38 Million
11,627 Added 41.07%
39,936 $19.6 Million
Q2 2023

Aug 11, 2023
BUY
$360.14 - $422.58 $2.34 Million - $2.74 Million
6,489 Added 29.74%
28,309 $11 Million
Q1 2023

May 15, 2023
BUY
$334.23 - $403.65 $247,330 - $298,701
740 Added 3.51%
21,820 $8.13 Million
Q4 2022

Feb 13, 2023
SELL
$342.17 - $402.31 $602,903 - $708,870
-1,762 Reduced 7.71%
21,080 $7.99 Million
Q3 2022

Nov 14, 2022
BUY
$343.2 - $395.75 $602,316 - $694,541
1,755 Added 8.32%
22,842 $8.06 Million
Q2 2022

Aug 12, 2022
BUY
$269.58 - $378.88 $1.27 Million - $1.79 Million
4,728 Added 28.9%
21,087 $7.99 Million
Q1 2022

May 13, 2022
SELL
$254.45 - $351.06 $140,710 - $194,136
-553 Reduced 3.27%
16,359 $5.16 Million
Q4 2021

Feb 08, 2022
BUY
$272.01 - $353.03 $834,254 - $1.08 Million
3,067 Added 22.15%
16,912 $5.92 Million
Q3 2021

Nov 15, 2021
SELL
$295.0 - $350.58 $2.54 Million - $3.02 Million
-8,612 Reduced 38.35%
13,845 $4.18 Million
Q2 2021

Aug 13, 2021
SELL
$257.11 - $319.92 $1.88 Million - $2.34 Million
-7,301 Reduced 24.53%
22,457 $6.76 Million
Q1 2021

May 12, 2021
BUY
$268.3 - $380.31 $886,731 - $1.26 Million
3,305 Added 12.49%
29,758 $8.2 Million
Q4 2020

Feb 11, 2021
SELL
$248.13 - $308.36 $1,985 - $2,466
-8 Reduced 0.03%
26,453 $7.78 Million
Q3 2020

Nov 16, 2020
BUY
$215.51 - $272.51 $1.49 Million - $1.88 Million
6,909 Added 35.34%
26,461 $6.95 Million
Q2 2020

Aug 14, 2020
BUY
$127.44 - $232.72 $324,844 - $593,203
2,549 Added 14.99%
19,552 $4.4 Million
Q1 2020

May 14, 2020
SELL
$108.83 - $165.23 $86,955 - $132,018
-799 Reduced 4.49%
17,003 $2.24 Million
Q4 2019

Feb 14, 2020
BUY
$106.59 - $164.21 $213,286 - $328,584
2,001 Added 12.66%
17,802 $2.86 Million
Q3 2019

Nov 13, 2019
BUY
$113.31 - $150.51 $1,473 - $1,956
13 Added 0.08%
15,801 $1.8 Million
Q2 2019

Aug 13, 2019
SELL
$115.0 - $141.58 $3,680 - $4,530
-32 Reduced 0.2%
15,788 $2.24 Million
Q1 2019

May 13, 2019
BUY
$98.85 - $134.59 $41,319 - $56,258
418 Added 2.71%
15,820 $1.98 Million
Q4 2018

Feb 12, 2019
SELL
$63.81 - $109.82 $20,100 - $34,593
-315 Reduced 2.0%
15,402 $1.48 Million
Q3 2018

Nov 14, 2018
BUY
$75.5 - $96.63 $249,074 - $318,782
3,299 Added 26.57%
15,717 $1.19 Million
Q2 2018

Sep 18, 2018
SELL
$74.84 - $100.16 $157,538 - $210,836
-2,105 Reduced 14.49%
12,418 $1.03 Million
Q2 2018

Aug 14, 2018
BUY
$74.84 - $100.16 $253,707 - $339,542
3,390 Added 30.45%
14,523 $1.2 Million
Q1 2018

May 09, 2018
BUY
$56.95 - $85.19 $634,024 - $948,420
11,133 New
11,133 $896,000

Others Institutions Holding ARGX

# of Institutions
400
Shares Held
30.9M
Call Options Held
376K
Put Options Held
489K
View Full List

About ARGENX SE

ARGX Quotes by TradingView
  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email